• Kiniksa Pharmaceuticals International will hold its annual shareholder meeting in London on May 29, 2026.
• Votes are scheduled on re-election of three Class II directors: Stephen R. Biggar, G. Bradley Cole, Barry D. Quart.
• Shareholders will also vote on keeping PricewaterhouseCoopers as UK statutory auditor through 2027, ratifying PwC as US independent registered public accounting firm for year ending Dec. 31, 2026.
• Additional items include authorizing audit committee to set PwC UK audit fees, receiving UK annual report for year ended Dec. 31, 2025.
• Advisory votes are set on UK directors’ remuneration report, UK remuneration policy, executive pay program for named executive officers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiniksa Pharmaceuticals International plc published the original content used to generate this news brief on May 08, 2026, and is solely responsible for the information contained therein.